JDRF Leadership: Leveraging Funds for Our Mission

To accelerate our mission to cure type 1 diabetes (T1D) and improve lives, we need to collaborate with other, like-minded organizations. That’s why we work to bring in additional supporters and funding to T1D research and therapy development. Through our advocacy, leadership, and expertise, JDRF maximizes each donation by attracting additional funding for cures research and advances to improve lives.

“I learned that you could get more money for research in one day from the federal government than you could get from a year of fundraising.”

— Lee Ducat, co-founder, JDRF

Our Research and Advocacy Goals

**Accelerate our mission** by continuing to advance research breakthroughs

**Investing in novel companies** driving T1D therapies through the JDRF T1D Fund and encourage private, for-profit investments in the T1D research and therapy development space

**$** Urge U.S. and international governments to sustain and increase T1D research funding

Our Leverage for Fiscal Year 2020

In FY2020, we leveraged more funds than ever before

For every **$1 JDRF committed** to T1D research, we attracted another **$3.50**

A total of **$506 million**—through funding from other organizations, corporations, and governments, in addition to JDRF—for T1D research and therapy development

Of that $506 million, **JDRF T1D Fund** catalyzed **$164 million** in private investment in companies developing T1D treatments and technologies

JDRF drew **$394M** in additional investments for T1D research—a 34.5% increase from FY19
By the Numbers—4 Fiscal Years

During the past 4 fiscal years, through JDRF’s research grants, JDRF T1D Fund investments, and equity investments other companies have made alongside the Fund, **$644M** has been directed to cure T1D and improve lives—with most of it focused on cures.

Our Latest Advances

JDRF has played a significant role in nearly every T1D advance of the last five decades, including these recent ones:

**Life-Changing Technology:** JDRF launched the Artificial Pancreas Project in 2006, and since then has put upwards of $140 million toward funding artificial pancreas research. We led efforts to accelerate the development of artificial pancreas systems and worked with the FDA to pave a clear pathway to regulatory approval. Now, more people—including children as young as age 2—have access to artificial pancreas systems.

**A Landmark Investment:** T1D Fund portfolio company Semma Therapeutics made headlines in 2019 when it was acquired by Vertex Pharmaceuticals for nearly $1 billion. Semma was founded in 2015 with the goal of commercializing beta cells derived from stem cells. The team had support from JDRF since 2000. In 2017, the T1D Fund provided an important investment in Semma at a critical time that helped validate their novel approach and, in turn, allowed Semma to attract a new major pharmaceutical company into the T1D space.

**Drug Delays T1D Onset for Nearly 3 Years:** In 2020, a disease-modifying therapy, teplizumab, was able to delay onset of T1D by nearly 3 years in people at-risk for developing the disease. JDRF had a hand in the development of teplizumab from nearly the beginning, from basic research in 1980s to clinical trials in recent-onset disease, and Provention Bio, which owns teplizumab, is a T1D Fund portfolio company. Teplizumab is currently under FDA review and could become the first approved disease-modifying therapy for T1D.